After the CLL genome was discovered to be globally hypomethylated, research for aberrantly methylated oncogene targets revealed that hypomethylation of the B cell lymphoma 2 (BCL2) gene, an important antiapoptotic gene, correlated with higher protein expression in CLL [22]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.